160 likes | 595 Views
Breast cancer 5 year survival rates (UK, 1975) by stage at diagnosis. 5-year survival (%). No. of patients. 75.7 73.5 71.4 70.8 69.9 68.4 68.1 62.5 62.5 61.8 58.8 43.9. 2,243 11,123 2,498 3,595 2,653 3,359 17,498 60,390 1,043 11,261 2,387 1,089. Switzerland. Finland.
E N D
Breast cancer 5 year survival rates (UK, 1975) by stage at diagnosis
5-year survival (%) No. of patients 75.7 73.5 71.4 70.8 69.9 68.4 68.1 62.5 62.5 61.8 58.8 43.9 2,243 11,123 2,498 3,595 2,653 3,359 17,498 60,390 1,043 11,261 2,387 1,089 Switzerland Finland France Italy Netherlands Germany Denmark England Spain Scotland Estonia Poland 0 20 40 60 80 100 Five-year survival (%) J Nat Cancer Inst 1995; 87: 1209 5-year survival in breast cancer (Europe; 1990)
Breast cancer demographics Patients (n=82,488) Proportion of patients (%) Mean age (years) Age at diagnosis (%)<5050 Tumour size (%)>2.0 cm2.0 cmunknown ER-positive ER-negative 75.1 63.3 20.179.9 28.865.16.1 24.9 56.9 35.764.3 41.450.18.5 Anderson WF et al. Breast Cancer Res Treat 2002; 76: 27–36 ER = oestrogen receptor
Breast cancer continuum: consistency of results on 5 years of tamoxifen Placebo Tamoxifen
Breast cancer incidence and mortality Incidence Mortality England France Germany Total EU USA n 10,846 10,811 17,692 73,592 39,800 n 34,176 35,726 48,098 210,631 211,300 Jemal A et al. CA Cancer J Clin 2003; 53: 5–26; Cancer Research UK. Cancer Stats – Incidence & Mortality UK, April 2003;Ferlay et al. IARC Press, 1999
Mortality Screening introduced 110 Age-standardised mortality from breastcancer in women aged 55-69,England and Wales, 1950-94 110 100 100 90 90 80 80 0 0 1950 60 70 80 87 90 94 Year Changes in incidence and mortality from breast cancer (UK, 1994) Incidence • In the UK in 1992, the incidence of breast cancer was 40% higher than in 1979 • Incidence of breast cancer in the UK (age 50–64) increased steeply following the introduction of screening in 1988 Quinn M, et al. Br Med J 1995; 311: 1391-1395
100 3-year event-free rate: 92% 90% 90 84.6% Estimated percentage still without recurrence as first event 80 70 Anastrozole (ATAC data) 70.5% Tamoxifen (ATAC data) 0 years 0 1 2 3 4 5+ Tamoxifen (EBCTCG overview) Control (EBCTCG overview) 1EBCTCG. The Lancet 1998; 351: 1451–1467 *ATAC data truncated at 42 months Improved Outlook in Early Breast Cancer:Indirect Comparison of ATAC data with EBCTCG 1995 Overview1(Hormone Receptor +ve Patients >50 Years)
Number of new breast cancer cases diagnosed and age-specific rates per 100,000 population, UK, 1999 Numberof newcases Rate per100,000population 6000 450 number 400 rates 5000 350 4000 300 250 3000 200 2000 150 100 1000 50 0 0 0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65- 69 70- 74 75- 79 80- 84 85+ Age at diagnosis Cancer Research UK, 2003
Survival from time of tumour recurrence:in all patients with advanced breast cancer 1974-1979 1980-1984 1985-1989 1990-1994 1995-2000